

Supporting Information

Room-temperature Pd(II)-catalyzed direct C–H alkynylation of phenylacetic amides with terminal alkyne

Cui-Hong Chen,^a Yun Chai,^a Zheng-Xin Zhou,^a Wei-Hao Rao,^b Bin Liu,^a Li Liu,^a Ran Xu,^a Yue-Jin Liu,^{*a} and Ming-Hua Zeng^{*a}

Hubei Collaborative Innovation Center for Advanced Chemical Materials, Ministry of Education Key
Laboratory for the Synthesis and Application of Organic Functional Molecules, and College of
Chemistry and Chemical Engineering, Hubei University, Wuhan, 430062, China.

Table of Contents:

1. General information	S2
2. Experimental Section	S3
2.1 Optimization of Reaction Conditions	S3
2.2 General Procedure for C-H Alkynylation	S4
2.3 Mechanistic Investigation	S23
2.4 Diversication of ortho-Alkynylated phenylacetic amides	S26
2.5 Gram-Scale Reaction	S27
2.6 Crystal structure data	S28
2.7 Chirality retention experiment	S30
3. Spectra	S32


1. General Information:

All reactions were carried out in a flame-dried, sealed Schlenk reaction tube under an atmosphere of air. Analytical thin-layer chromatography was performed on glass plates coated with 0.25 mm 230–400 mesh silica gel containing a fluorescent indicator (Merck). Flash silica gel column chromatography was performed on silica gel 60N (spherical and neutral, 140–325 mesh) as described by Still. NMR spectra were measured on a Varian INOVA600 spectrometer. ^1H NMR spectra were recorded at 500 MHz in CDCl_3 were referenced internally to tetramethylsilane as a standard, and ^{13}C NMR spectra were recorded at 125 MHz and referenced to the solvent resonance. High resolution mass spectra (HRMS) were recorded on the Thermo Scientific Exactive Plus equipped with ESI ionization source. The enantiomeric excess values were determined by chiral HPLC with an Agilent instrument and a Daicel CHIRALCEL and CHIRALPAK column and Nu-Analytical HPLC Column. The chiral HPLC methods were calibrated with the corresponding racemic mixtures. The racemic products used to determine the ee values were obtained under achiral-catalyst conditions.

Materials. Unless otherwise noted, materials were purchased from Tokyo Chemical Industry Co., Aldrich Inc., Alfa Aesar, Adamas, and other commercial suppliers and used as received. $\text{Pd}(\text{OAc})_2$ was purchased from Alfa Aesar and used as received.

2. Experimental Section

2.1 Optimization of Conditions




Entry	Ligand (20 mol %)	[Ag]	Additive	Solvent	Yield ^a of 3a
1	<i>N</i> -Boc-Ala-OH	AgTFA	/	DCE	0%
2	<i>N</i> -Boc-Ala-OH	AgTFA	/	toluene	0%
3	<i>N</i> -Boc-Ala-OH	AgTFA	/	<i>t</i> -AmylOH	0%
4	<i>N</i> -Boc-Ala-OH	AgTFA	NBS	<i>t</i> -AmylOH	77%
5	<i>N</i> -Boc-Ala-OH	AgTFA	NCS	<i>t</i> -AmylOH	< 5%
6	<i>N</i> -Boc-Ala-OH	AgTFA	NIS	<i>t</i> -AmylOH	< 5%
7	<i>N</i> -Boc-Ala-OH	AgTFA	I ₂	<i>t</i> -AmylOH	20%
8	<i>N</i> -Boc-Ala-OH	AgNO ₃	NBS	<i>t</i> -AmylOH	63%
9	<i>N</i> -Boc-Ala-OH	Ag ₂ CO ₃	NBS	<i>t</i> -AmylOH	< 5%
10	<i>N</i> -Boc-Ala-OH	Ag ₂ O	NBS	<i>t</i> -AmylOH	< 5%
11	PivOH	AgTFA	NBS	<i>t</i> -AmylOH	61%
12	AdCO ₂ H	AgTFA	NBS	<i>t</i> -AmylOH	62%
13	<i>N</i> -Boc-Val-OH	AgTFA	NBS	<i>t</i> -AmylOH	64%
14	<i>N</i> -Boc-Ile-OH	AgTFA	NBS	<i>t</i> -AmylOH	62%
15	<i>N</i> -Ac-Ala-OH	AgTFA	NBS	<i>t</i> -AmylOH	66%
16 ^b	<i>N</i> -Boc-Ala-OH	AgTFA	NBS	<i>t</i> -AmylOH	78% ^c (99% ee)
17	CH ₃ CO ₂ H	AgTFA	NBS	<i>t</i> -AmylOH	58%
18	CF ₃ CO ₂ H	AgTFA	NBS	<i>t</i> -AmylOH	60%
19 ^d	<i>N</i> -Boc-Ala-OH	AgTFA	NBS	<i>t</i> -AmylOH	35%


^aConditions: 1a (0.1 mmol), 2 (0.15 mmol), Pd(OAc)₂ (10 mol %), ligand (20 mol %), [Ag] (0.12 mmol), additive (0.12 mmol), solvent (1 mL), at 60 °C for 24 h under air. Isolated yields. ^bmono:di = 5:1.

^cConducted at rt. ^dPd(OAc)₂ (5 mol %) was used.

2.2 General Procedure for C-H alkylation




A mixture of **1** (0.2 mmol), $\text{Pd}(\text{OAc})_2$ (10 mol%), **2** (0.24 mmol), Boc-D-Ala-OH (20 mol%), $\text{CF}_3\text{CO}_2\text{Ag}$ (0.24 mmol) and NBS (0.24 mmol), Tertiary amyl alcohol (1 mL) in a 35 mL sealed tube was heated at room temperature or 60 °C for 10 h under an air atmosphere. The reaction mixture was cooled to room temperature and concentrated under a reduced pressure. The resulting residue was purified by column chromatography on silica gel to give the corresponding product **3**.




(S)-2-(4-isobutyl-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)propanamide **3a**

^1H NMR (400 MHz, CDCl_3) δ 9.88 (s, 1H), 8.78 (dd, $J = 7.6, 1.2$ Hz, 1H), 8.63 (dd, $J = 4.4, 1.6$ Hz, 1H), 8.09 – 8.07 (m, 1H), 7.52 – 7.43 (m, 3H), 7.38 – 7.34 (m, 2H), 7.12 (dd, $J = 8.0, 1.2$ Hz, 1H), 4.59 (q, $J = 7.2$ Hz, 1H), 2.43 (d, $J = 7.2$ Hz, 2H), 1.92–1.82 (m, 1H), 1.65 (d, $J = 7.2$ Hz, 4H), 1.16 – 1.10 (m, 21H), 0.91 (d, $J = 6.8$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.7, 148.1, 140.8, 140.6, 138.7, 136.13, 134.9, 133.6, 130.3, 127.9, 127.4, 126.7, 122.9, 121.5, 121.4, 116.5, 105.5, 95.2, 45.6, 44.9, 30.2, 22.5, 18.8, 18.6, 11.5; HRMS (EI-TOF) calcd for $\text{C}_{33}\text{H}_{45}\text{N}_2\text{OSi}$ (M^+): 513.3301, found: 513.3286.




(S)-2-(6-methoxy-3-((triisopropylsilyl)ethynyl)naphthalen-2-yl)-N-(quinolin-8-yl)propanamide 3b

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.96 (s, 1H), 8.82 (d, $J = 7.2$ Hz, 1H), 8.60 (dd, $J = 4.0$, 1.6 Hz, 1H), 8.07 (dd, $J = 8.0$, 1.2 Hz, 1H), 8.01 (s, 1H), 7.92 (s, 1H), 7.69 (d, $J = 9.2$ Hz, 1H), 7.53 – 7.44 (m, 2H), 7.35 (dd, $J = 8.4$, 4.4 Hz, 1H), 7.12 (dd, $J = 8.8$, 2.4 Hz, 1H), 7.06 (d, $J = 2.4$ Hz, 1H), 4.70 (q, $J = 7.2$ Hz, 1H), 3.89 (s, 3H), 1.75 (d, $J = 7.2$ Hz, 3H), 1.21 – 1.16 (m, 21H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 172.8, 158.1, 148.1, 138.6, 137.4, 136.2, 134.9, 133.2, 132.2, 129.6, 129.0, 127.9, 127.39, 125.7, 121.7, 121.5, 121.4, 120.0, 116.4, 105.5, 105.1, 95.7, 55.4, 45.7, 19.1, 18.9, 11.5; **HRMS** (EI-TOF) calcd for $\text{C}_{34}\text{H}_{41}\text{N}_2\text{O}_2\text{Si}$ (M^+): 537.2937, found: 537.2924.




(S)-N-(quinolin-8-yl)-2-(2-((triisopropylsilyl)ethynyl)phenyl)propanamide 3c

$^1\text{H NMR}$ (501 MHz, CDCl_3) δ 9.97 (s, 1H), 8.85 – 8.84 (m, 1H), 8.71 (dd, $J = 4.0$, 1.5 Hz, 1H), 8.11 (dd, $J = 8.0$, 1.0 Hz, 1H), 7.62 (d, $J = 8.0$ Hz, 2H), 7.56 – 7.48 (m, 2H), 7.42 – 7.37 (m, 2H), 7.30 – 7.26 (m, 1H), 4.71 (q, $J = 6.5$ Hz, 1H), 1.72 (d, $J = 7.0$ Hz, 3H), 1.21-1.20 (m, 21H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 172.4, 148.1, 143.5, 138.6, 136.2, 134.8, 133.2, 129.3, 127.9, 127.4, 127.0, 126.9, 123.1, 121.6, 121.4, 116.5, 105.1, 95.8, 45.8, 18.8, 18.6, 11.5; **HRMS** (EI-TOF) calcd for $\text{C}_{29}\text{H}_{37}\text{N}_2\text{OSi}$ (M^+): 457.2675, found: 457.2663.




(S)-2-(5-benzoyl-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)propanamide 3d

¹H NMR (400 MHz, CDCl₃) δ 9.84 (s, 1H), 8.67 (d, *J* = 6.4 Hz, 1H), 8.59 (d, *J* = 2.8 Hz, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.88 (s, 1H), 7.68 – 7.58 (m, 4H), 7.45 – 7.38 (m, 3H), 7.31 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.24 (t, *J* = 7.6 Hz, 2H), 4.59 (d, *J* = 7.2 Hz, 1H), 1.61 (d, *J* = 6.8 Hz, 3H), 1.09-1.05 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 195.9, 171.9, 147.95, 143.4, 138.3, 137.8, 137.4, 136.8, 134.6, 133.3, 132.7, 130.2, 128.9, 128.5, 128.4, 128.1, 127.6, 127.3, 121.7, 121.6, 117.1, 104.3, 99.7, 46.0, 18.8, 18.5, 11.5; **HRMS** (EI-TOF) calcd for C₃₆H₄₁N₂O₂Si (M⁺): 561.2937, found: 561.2922.



2-(4-methyl-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)propanamide
3e


¹H NMR (400 MHz, CDCl₃) δ 9.90 (s, 1H), 8.78 (d, *J* = 7.2 Hz, 1H), 8.67 (d, *J* = 2.8 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.51 – 7.35 (m, 5H), 7.13 (d, *J* = 8.0 Hz, 1H), 4.60 (q, *J* = 6.8 Hz, 1H), 2.30 (s, 3H), 1.64 (d, *J* = 6.8 Hz, 3H), 1.14 (s, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 172.7, 148.1, 140.6, 138.5, 136.7, 136.2, 134.9, 133.5, 130.2, 127.9, 127.4, 126.7, 122.9, 121.5, 121.4, 116.5, 105.3, 95.2, 45.5, 20.9, 18.8, 18.6, 11.5; **HRMS** (EI-TOF) calcd for C₃₀H₃₉FN₂O₂Si (M⁺): 471.2832, found: 471.2812.



2-(4,5-dimethoxy-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)propanamide
3f


¹H NMR (501 MHz, CDCl₃) δ 9.92 (s, 1H), 8.77 (d, *J* = 6.5 Hz, 1H), 8.69 (dd, *J* = 4.0, 1.5 Hz, 1H), 8.10 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.52 – 7.45 (m, 2H), 7.39 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.05 (s, 1H), 7.00 (s, 1H), 4.61 (q, *J* = 7.0 Hz, 1H), 3.88 (d, *J* = 3.5 Hz, 6H), 1.62 (d, *J* = 7.0 Hz, 3H), 1.17-1.15 (m, 21H); **¹³C NMR** (126 MHz, CDCl₃) δ 171.7, 149.3, 147.2, 146.8, 137.7, 136.2, 135.2, 133.9, 127.0, 126.4, 120.6, 120.5, 115.5,

114.1, 114.0, 108.5, 106.4, 104.3, 92.8, 55.2, 55.1, 44.5, 17.9, 17.8, 10.6; **HRMS** (EI-TOF) calcd for $C_{31}H_{41}N_2O_3Si$ (M^+): 517.2886, found: 517.2870.




N-(quinolin-8-yl)-2-(2-((triisopropylsilyl)ethynyl)phenyl)butanamide 3g

1H NMR (501 MHz, $CDCl_3$) δ 9.94 (s, 1H), 8.79 (d, $J = 7.5$ Hz, 1H), 8.69 (dd, $J = 4.5$, 1.5 Hz, 1H), 8.08 (dd, $J = 8.0$, 1.5 Hz, 1H), 7.64 (d, $J = 8.0$ Hz, 1H), 7.55 – 7.54 (m, 1H), 7.51 – 7.43 (m, 2H), 7.38 (dd, $J = 8.5$, 4.5 Hz, 1H), 7.31 (t, $J = 7.5$ Hz, 1H), 7.21 – 7.18 (m, 1H), 4.47 (t, $J = 7.5$ Hz, 1H), 2.34 – 2.25 (m, 1H), 1.99 – 1.90 (m, 1H), 1.20 – 1.18 (m, 21H), 1.00 (t, $J = 7.5$ Hz, 3H); **^{13}C NMR** (101 MHz, $CDCl_3$) δ 172.0, 148.1, 142.1, 138.6, 136.2, 134.8, 133.0, 129.2, 127.9, 127.4, 126.9, 126.9, 123.4, 121.6, 121.5, 116.5, 105.4, 95.3, 53.2, 27.3, 18.9, 12.4, 11.5; **HRMS** (EI-TOF) calcd for $C_{30}H_{39}N_2OSi$ (M^+): 471.2832, found: 471.2817.




2-(4-chloro-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)pentanamide 3h

1H NMR (400 MHz, $CDCl_3$) δ 9.95 (s, 1H), 8.77 – 8.71 (m, 2H), 8.10 (d, $J = 8.4$ Hz, 1H), 7.61 (d, $J = 8.4$ Hz, 1H), 7.51 – 7.45 (m, 3H), 7.40 (dd, $J = 8.4$, 4.4 Hz, 1H), 7.29 (d, $J = 7.6$ Hz, 1H), 4.49 (t, $J = 7.2$ Hz, 1H), 2.27 – 2.18 (m, 1H), 1.91 – 1.82 (m, 1H), 1.69 (d, $J = 6.8$ Hz, 1H), 1.47 – 1.32 (m, 2H), 1.19 (s, 21H), 0.96 (t, $J = 7.2$ Hz, 3H); **^{13}C NMR** (101 MHz, $CDCl_3$) δ 171.6, 148.2, 140.7, 138.6, 136.2, 134.7, 132.6, 132.5, 129.4, 128.5, 128.0, 127.4, 124.9, 121.7, 121.7, 116.6, 103.9, 97.0, 50.8, 36.3, 21.1, 18.9, 14.2, 11.5; **HRMS** (EI-TOF) calcd for $C_{31}H_{40}ClN_2OSi$ (M^+): 519.2598, found: 519.2589.




2-(4-chloro-2-((triisopropylsilyl)ethynyl)phenyl)-3-methyl-N-(quinolin-8-yl)butanamide 3i

^1H NMR (400 MHz, CDCl_3) δ 9.99 (s, 1H), 8.78 – 8.73 (m, 2H), 8.12 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.52 – 7.41 (m, 4H), 7.29 (dd, J = 8.4, 2.0 Hz, 1H), 4.18 (d, J = 10.5 Hz, 1H), 2.53 – 2.47 (m, 1H), 1.28 – 1.22 (m, 21H), 1.16 (d, J = 6.4 Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.6, 148.1, 140.1, 138.5, 136.2, 134.6, 132.5, 132.2, 129.4, 128.5, 128.0, 127.3, 125.3, 121.7, 121.6, 116.7, 104.3, 96.7, 58.6, 33.2, 21.9, 19.8, 19.0, 11.6; HRMS (EI-TOF) calcd for $\text{C}_{31}\text{H}_{40}\text{ClN}_2\text{OSi}$ (M^+): 519.2598, found: 518.2588.




(S)-2-oxo-2-(quinolin-8-ylamino)-1-(2-((triisopropylsilyl)ethynyl)phenyl)ethyl acetate 3j

^1H NMR (400 MHz, CDCl_3) δ 10.38 (s, 1H), 8.65 – 8.64 (m, 2H), 8.00 (d, J = 8.4 Hz, 1H), 7.51 (t, J = 7.2 Hz, 2H), 7.39-7.38 (m, 2H), 7.31 (dd, J = 8.0, 4.4 Hz, 1H), 7.26-7.20 (m, 2H), 6.81 – 6.80 (m, 1H), 2.20 (s, 3H), 1.01 (s, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 169.7, 166.6, 148.3, 138.6, 137.0, 136.5, 134.0, 133.6, 129.0, 129.0, 128.2, 128.1, 127.5, 123.9, 122.1, 121.7, 117.2, 103.9, 97.1, 74.3, 21.0, 18.8, 18.8, 11.5; HRMS (EI-TOF) calcd for $\text{C}_{30}\text{H}_{37}\text{N}_2\text{O}_3\text{Si}$ (M^+): 501.2573, found: 501.2559.




1-(2,6-bis(3,3-diisopropyl-4-methylpent-1-yn-1-yl)phenyl)-2-oxo-2-(quinolin-8-ylamino)ethyl acetate 3j

¹H NMR (501 MHz, CDCl₃) δ 10.62 (s, 1H), 8.80 – 8.75 (m, 2H), 8.14 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.53 – 7.49 (m, 4H), 7.43 (dd, *J* = 8.5, 4.0 Hz, 1H), 7.33 (s, 1H), 7.27 – 7.26 (m, 1H), 2.33 (s, 3H), 0.99 – 0.95 (m, 42H); ¹³C NMR (101 MHz, CDCl₃) δ 169.2, 165.8, 148.2, 138.8, 138.2, 136.3, 134.3, 134.2, 128.6, 127.9, 127.5, 121.7, 121.6, 116.8, 103.8, 97.4, 73.4, 21.1, 18.7, 18.6, 11.4; HRMS (EI-TOF) calcd for C₄₁H₅₇N₂O₃Si₂ (M⁺): 681.3908, found: 681.3901.



2-(1,3-dioxoisindolin-2-yl)-N-(quinolin-8-yl)-2-((triisopropylsilyl)ethynyl)phenylacetamide 3k


¹H NMR (501 MHz, CDCl₃) δ 10.17 (s, 1H), 8.78 (dd, *J* = 6.5, 2.0 Hz, 1H), 8.55 (dd, *J* = 4.5, 2.0 Hz, 1H), 8.12 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.94 – 7.92 (m, 2H), 7.83 – 7.72 (m, 4H), 7.54 – 7.45 (m, 4H), 7.38 (dd, *J* = 8.5, 4.5 Hz, 1H), 6.90 (s, 1H), 1.10 – 1.03 (m, 21H); ¹³C NMR (101 MHz, CDCl₃) δ 168.0, 165.1, 148.3, 138.7, 136.3, 136.1, 134.2, 134.1, 133.5, 132.2, 129.3, 128.9, 128.8, 127.8, 127.3, 124.7, 123.7, 122.0, 121.6, 116.5, 103.6, 98.4, 57.5, 18.6, 11.3; HRMS (EI-TOF) calcd for C₃₆H₃₈N₃O₃Si (M⁺): 588.2682, found: 588.2672.



2-(4-chloro-2-((triisopropylsilyl)ethynyl)phenyl)-3-phenyl-N-(quinolin-8-yl)propanamide 3i


¹H NMR (400 MHz, CDCl₃) δ 9.85 (s, 1H), 8.73 (d, *J* = 7.2 Hz, 1H), 8.65 – 8.64 (m, 1H), 8.09 – 8.07 (m, 1H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.50 – 7.43 (m, 3H), 7.37 (dd, *J* =

8.0, 4.0 Hz, 1H), 7.30 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.24 – 7.09 (m, 5H), 4.81 (t, $J = 7.6$ Hz, 1H), 3.61 (dd, $J = 14.8, 8.4$ Hz, 1H), 3.15 (dd, $J = 13.6, 6.8$ Hz, 1H), 1.21 – 1.16 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 170.7, 148.0, 139.9, 139.1, 138.4, 136.3, 134.6, 132.9, 132.8, 129.4, 129.2, 128.9, 128.4, 128.0, 127.4, 126.4, 124.9, 121.7, 121.6, 116.9, 103.8, 97.3, 52.7, 39.7, 18.9, 11.5; HRMS (EI-TOF) calcd for $\text{C}_{35}\text{H}_{40}\text{ClN}_2\text{OSi}$ (M^+): 567.2598, found: 567.2579.



2-cyclopentyl-N-(quinolin-8-yl)-2-(2-((triisopropylsilyl)ethynyl)phenyl)acetamide
3m


^1H NMR (400 MHz, CDCl_3) δ 9.98 (s, 1H), 8.79 (d, $J = 7.2$ Hz, 1H), 8.72 (d, $J = 3.2$ Hz, 1H), 8.09 (d, $J = 8.0$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.53 – 7.39 (m, 4H), 7.31 (t, $J = 7.6$ Hz, 1H), 7.17 (t, $J = 7.6$ Hz, 1H), 4.38 (d, $J = 10.8$ Hz, 1H), 2.81 – 2.74 (m, 1H), 2.08 – 2.05 (m, 1H), 1.64 (d, $J = 8.4$ Hz, 4H), 1.51 – 1.40 (m, 3H), 1.23 (d, $J = 5.4$ Hz, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.1, 148.1, 142.0, 138.5, 136.2, 134.8, 132.8, 129.1, 127.9, 127.9, 127.2, 126.7, 123.3, 121.6, 121.5, 116.6, 105.8, 95.0, 57.0, 44.6, 32.2, 30.1, 25.5, 25.2, 19.0, 11.6; HRMS (EI-TOF) calcd for $\text{C}_{33}\text{H}_{43}\text{N}_2\text{OSi}$ (M^+): 511.3139, found: 511.3134.



2-cyclohexyl-N-(quinolin-8-yl)-2-(2-((triisopropylsilyl)ethynyl)phenyl)acetamide
3n


^1H NMR (501 MHz, CDCl_3) δ 9.92 (s, 1H), 8.72 (dd, $J = 7.5, 1.5$ Hz, 1H), 8.65 (dd, $J = 4.0, 1.5$ Hz, 1H), 8.02 (dd, $J = 8.5, 1.5$ Hz, 1H), 7.71 (d, $J = 8.0$ Hz, 1H), 7.43 – 7.36 (m, 3H), 7.32 (dd, $J = 8.5, 4.5$ Hz, 1H), 7.24 (t, $J = 7.5$ Hz, 1H), 7.09 (t, $J = 7.5$

Hz, 1H), 4.24 (d, $J = 10.5$ Hz, 1H), 2.17 (q, $J = 11.0$ Hz, 1H), 1.98 (d, $J = 13.0$ Hz, 1H), 1.66 – 1.57 (m, 3H), 1.29 – 1.21 (m, 3H), 1.20 – 1.16 (m, 21H), 1.12 – 1.07 (m, 2H), 1.01 – 0.94 (m, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 172.7, 148.1, 140.8, 140.6, 138.7, 136.1, 135.0, 133.6, 130.3, 128.0, 127.4, 126.7, 122.9, 121.5, 121.4, 116.5, 105.5, 95.2, 45.6, 44.9, 30.2, 22.5, 18.9, 18.62, 11.5; HRMS (EI-TOF) calcd for $\text{C}_{34}\text{H}_{45}\text{N}_2\text{OSi}$ (M^+): 525.3296, found: 525.3289.




N-(quinolin-8-yl)-8-((triisopropylsilyl)ethynyl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide 3o

^1H NMR (501 MHz, CDCl_3) δ 9.74 (s, 1H), 8.68 (d, $J = 7.5$ Hz, 1H), 8.48 – 8.47 (m, 1H), 7.96 (d, $J = 8.5$ Hz, 1H), 7.40 – 7.32 (m, 3H), 7.24 (dd, $J = 8.0, 4.0$ Hz, 1H), 7.17 – 7.11 (m, 2H), 4.27 (d, $J = 3.5$ Hz, 1H), 2.86 – 2.71 (m, 2H), 2.53 – 2.51 (m, 1H), 1.98 – 1.76 (m, 3H), 0.81 – 0.77 (m, 21H); ^{13}C NMR (126 MHz, CDCl_3) δ 172.4, 148.0, 138.6, 138.5, 136.0, 135.8, 134.8, 131.2, 130.0, 127.8, 127.4, 127.0, 125.0, 121.4, 121.2, 116.2, 104.8, 96.4, 46.9, 29.6, 27.8, 19.8, 18.6, 18.5, 11.2; HRMS (EI-TOF) calcd for $\text{C}_{31}\text{H}_{39}\text{N}_2\text{OSi}$ (M^+): 483.2832, found: 483.2815.




2-(2-methyl-6-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5a

^1H NMR (501 MHz, CDCl_3) δ 9.78 (s, 1H), 8.65 (dd, $J = 7.5, 1.0$ Hz, 1H), 8.53 (dd, $J = 4.0, 1.5$ Hz, 1H), 7.98 (dd, $J = 8.5, 1.5$ Hz, 1H), 7.42 – 7.34 (m, 3H), 7.26 (dd, $J = 8.0, 4.0$ Hz, 1H), 7.15 – 7.11 (m, 2H), 4.15 (s, 2H), 2.31 (s, 3H), 0.93-0.90 (m, 21H); ^{13}C NMR (126 MHz, CDCl_3) δ 168.5, 148.1, 138.5, 138.0, 136.1, 135.3, 134.6, 130.9, 127.8, 127.4, 127.3, 124.7, 121.4, 121.4, 116.3, 105.5, 95.4, 41.1, 20.4, 18.6, 11.3; HRMS (EI-TOF) calcd for $\text{C}_{29}\text{H}_{37}\text{N}_2\text{OSi}$ (M^+): 457.2675, found: 457.2582.




2-(2-fluoro-6-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5b

^1H NMR (400 MHz, CDCl_3) δ 9.93 (s, 1H), 8.74 (d, $J = 7.2$ Hz, 1H), 8.68 (dd, $J = 4.4$, 1.6 Hz, 1H), 8.10 (d, $J = 8.4$ Hz, 1H), 7.50 – 7.37 (m, 4H), 7.29 – 7.24 (m, 1H), 7.14 – 7.09 (m, 1H), 4.19 (s, 2H), 1.02 – 0.96 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 167.5, 161.5 (d, $J = 245.5$ Hz), 148.0, 138.4, 136.5, 134.6, 128.9, 128.8 (d, $J = 5.7$ Hz), 128.0, 127.5, 126.6 (d, $J = 5.1$ Hz), 124.4 (d, $J = 17.0$ Hz), 121.5, 116.8, 116.2, 116.0, 103.7 (d, $J = 3.8$ Hz), 97.0, 36.6 (d, $J = 2.4$ Hz), 18.7, 11.3; **HRMS** (EI-TOF) calcd for $\text{C}_{28}\text{H}_{34}\text{FN}_2\text{OSi}$ (M^+): 461.2424, found: 461.2328.




2-(2-chloro-6-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5c

^1H NMR (501 MHz, CDCl_3) δ 9.75 (s, 1H), 8.63 (dd, $J = 7.0$, 1.5 Hz, 1H), 8.59 (dd, $J = 4.0$, 1.5 Hz, 1H), 8.02 (dd, $J = 8.5$, 1.5 Hz, 1H), 7.71 (d, $J = 7.5$ Hz, 1H), 7.62 (d, $J = 8.0$ Hz, 1H), 7.41 – 7.29 (m, 4H), 4.31 (s, 2H), 0.88 – 0.83 (m, 21H); ^{13}C NMR (126 MHz, CDCl_3) δ 167.3, 148.1, 138.4, 136.2, 135.7, 135.0, 134.5, 131.5, 129.9, 128.4, 128.4, 127.8, 127.4, 126.5, 121.5, 126.5, 126.4, 116.4, 104.1, 97.1, 41.3, 18.6, 11.2; **HRMS** (EI-TOF) calcd for $\text{C}_{28}\text{H}_{34}\text{ClN}_2\text{OSi}$ (M^+): 477.2129, found: 477.2035.




**N-(quinolin-8-yl)-2-(2-(trifluoromethyl)-6-
((triisopropylsilyl)ethynyl)phenyl)acetamide 5d**

¹H NMR (501 MHz, CDCl₃) δ 9.81 (s, 1H), 8.66 (d, *J* = 7.5 Hz, 1H), 8.59 – 8.58 (m, 1H), 8.01 (d, *J* = 8.0 Hz, 1H), 7.44 – 7.29 (m, 5H), 7.17 – 7.14 (m, 1H), 4.28 (s, 2H), 0.94 – 0.90 (m, 21H); **¹³C NMR** (126 MHz, CDCl₃) δ 167.1, 148.0, 138.4, 136.4, 136.3, 135.3, 134.5, 130.2 (q, *J* = 30.1 Hz), 127.8, 127.5, 127.4, 126.1 (q, *J* = 5.3 Hz), 124.1 (q, *J* = 274.3 Hz), 121.5, 121.4, 116.4, 103.4, 98.4, 40.2, 18.5, 11.2; **HRMS** (EI-TOF) calcd for C₂₉H₃₄F₃N₂OSi (M⁺): 511.2392, found: 511.2292.



2-(5-methyl-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5e


¹H NMR (501 MHz, CDCl₃) δ 9.83 (s, 1H), 8.68 (dd, *J* = 7.5, 1.5 Hz, 1H), 8.57 (dd, *J* = 4.0, 1.5 Hz, 1H), 7.99 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.42 – 7.35 (m, 3H), 7.28 (dd, *J* = 8.5, 4.0 Hz, 1H), 7.18 (s, 1H), 7.00 (dd, *J* = 8.0, 1.0 Hz, 1H), 4.01 (s, 2H), 2.27 (s, 3H), 0.95 – 0.92 (m, 21H); **¹³C NMR** (126 MHz, CDCl₃) δ 169.0, 148.1, 139.2, 138.6, 136.7, 136.2, 134.7, 133.1, 130.9, 128.2, 127.9, 127.4, 121.5, 121.5, 121.2, 116.5, 105.1, 94.9, 43.7, 21.6, 18.7, 11.4; **HRMS** (EI-TOF) calcd for C₂₉H₃₇N₂OSi (M⁺): 457.2675, found: 457.2582.



2-(5-methoxy-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5f


¹H NMR (400 MHz, CDCl₃) δ 9.93 (s, 1H), 8.75 (dd, *J* = 7.6, 1.6 Hz, 1H), 8.66 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.07 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.53 – 7.42 (m, 3H), 7.36 (dd, *J* = 8.4, 4.4 Hz, 1H), 7.00 (d, *J* = 2.4 Hz, 1H), 6.82 (dd, *J* = 8.8, 2.8 Hz, 1H), 4.11 (s, 2H), 3.81 (s, 3H), 1.02 (d, *J* = 1.9 Hz, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 168.5, 159.8, 148.0, 138.4, 136.0, 134.5, 134.3, 127.7, 127.2, 121.4, 121.4, 116.4, 116.2, 115.1, 113.4 ,

104.8, 93.8, 55.3, 43.8, 18.5, 11.2; **HRMS** (EI-TOF) calcd for $C_{29}H_{37}N_2O_2Si$ (M^+): 473.2624, found: 473.2532.




2-(5-fluoro-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5g

1H NMR (501 MHz, $CDCl_3$) δ 9.84 (s, 1H), 8.67 (dd, $J = 7.0, 1.0$ Hz, 1H), 8.61 (dd, $J = 4.0, 1.5$ Hz, 1H), 8.04 (dd, $J = 8.5, 1.5$ Hz, 1H), 7.49-7.46 (m, 1H), 7.44 – 7.39 (m, 2H), 7.32 (dd, $J = 8.5, 4.5$ Hz, 1H), 7.12 (dd, $J = 9.0, 2.5$ Hz, 1H), 6.91 (td, $J = 8.5, 2.5$ Hz, 1H), 4.04 (s, 2H), 0.96 – 0.93 (m, 21H); **^{13}C NMR** (126 MHz, $CDCl_3$) δ 168.1, 162.6 (d, $J = 250.6$ Hz), 148.2, 139.5 (d, $J = 8.2$ Hz), 138.6, 136.3, 134.9 (d, $J = 8.6$ Hz), 134.5, 128.0, 127.4, 121.7, 121.6, 120.3 (d, $J = 3.3$ Hz), 117.3 (d, $J = 22.6$ Hz), 116.7, 114.7 (d, $J = 22.1$ Hz), 104.0, 95.6 (d, $J = 1.5$ Hz), 43.6 (d, $J = 1.4$ Hz), 18.7, 11.4; **HRMS** (EI-TOF) calcd for $C_{28}H_{34}FN_2OSi$ (M^+): 461.2424, found: 461.2330.




2-(5-chloro-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5h

1H NMR (400 MHz, $CDCl_3$) δ 9.92 (s, 1H), 8.74 (dd, $J = 7.2, 2.0$ Hz, 1H), 8.70 (dd, $J = 4.0, 1.6$ Hz, 1H), 8.11 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.52 – 7.46 (m, 4H), 7.40 (dd, $J = 8.4, 4.0$ Hz, 1H), 7.28 – 7.25 (m, 1H), 4.09 (s, 2H), 1.05 – 0.99 (m, 21H); **^{13}C NMR** (101 MHz, $CDCl_3$) δ 168.0, 148.2, 138.5, 138.6, 136.3, 134.7, 134.5, 134.2, 130.3, 127.9, 127.7, 127.4, 122.7, 121.6, 121.7, 116.6, 103.9, 97.1, 43.4, 18.7, 11.3; **HRMS** (EI-TOF) calcd for $C_{28}H_{34}ClN_2OSi$ (M^+): 477.2129, found: 477.2034.




2-(5-cyano-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5i

¹H NMR (400 MHz, CDCl₃) δ 9.92 (s, 1H), 8.73 – 8.70 (m, 2H), 8.15 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.84 (d, *J* = 1.2 Hz, 1H), 7.63 – 7.58 (m, 2H), 7.52 – 7.50 (m, 2H), 7.44 (dd, *J* = 8.4, 4.4 Hz, 1H), 4.18 (s, 2H), 1.05 – 1.01 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 167.3, 148.3, 142.0, 138.5, 136.4, 134.3, 131.8, 131.2, 128.0, 127.5, 125.6, 121.8, 122.0, 118.1, 116.7, 111.7, 102.5, 99.4, 43.6, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₂₉H₃₄N₃OSi₂ (M⁺): 468.2471, found: 468.2378.



N-(quinolin-8-yl)-2-(5-(trifluoromethyl)-2-((triisopropylsilyl)ethynyl)phenyl)acetamide 5j


¹H NMR (400 MHz, CDCl₃) δ 9.92 (s, 1H), 8.73 (dd, *J* = 6.8, 2.0 Hz, 1H), 8.69 (dd, *J* = 4.4, 1.6 Hz, 1H), 8.11 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.74 (s, 1H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.56 – 7.45 (m, 3H), 7.40 (dd, *J* = 8.3, 4.2 Hz, 1H), 4.18 (s, 2H), 1.07 – 0.99 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 167.7, 148.2, 138.6, 137.7, 136.3, 134.4, 133.5, 130.6 (q, *J* = 32.5 Hz), 128.0, 127.9 (q, *J* = 11.3 Hz), 127.4, 127.2 (q, *J* = 3.8 Hz), 124.2 (q, *J* = 3.6 Hz), 123.9 (q, *J* = 270.7 Hz), 121.7, 121.6, 116.6, 103.6, 99.2, 43.4, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₂₉H₃₄F₃N₂OSi (M⁺): 511.2392, found: 511.2291.



2-(4-methyl-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5k


¹H NMR (400 MHz, CDCl₃) δ 9.90 (s, 1H), 8.76 (dd, *J* = 7.2, 1.6 Hz, 1H), 8.68 (dd, *J* = 4.0, 1.6 Hz, 1H), 8.11 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.52 – 7.33 (m, 5H), 7.17 (dd, *J* = 8.0, 1.2 Hz, 1H), 4.09 (s, 2H), 2.35 (s, 3H), 1.05 – 1.00 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 169.2, 148.1, 138.6, 137.1, 136.2, 134.7, 133.9, 133.6, 130.1, 129.9,

127.9, 127.4, 123.9, 121.5, 121.5, 116.5, 105.1, 95.3, 43.4, 21.0, 18.7, 11.3; **HRMS** (EI-TOF) calcd for $C_{29}H_{37}N_2OSi$ (M^+): 457.2675, found: 457.2581.




2-(4-methyl-2,6-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5k

1H NMR (400 MHz, $CDCl_3$) δ 9.78 (s, 1H), 8.72 (dd, $J = 7.2, 1.6$ Hz, 1H), 8.65 (dd, $J = 4.4, 1.6$ Hz, 1H), 8.09 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.50 – 7.42 (m, 2H), 7.38 – 7.35 (m, 3H), 4.36 (s, 2H), 2.35 (s, 3H), 1.02 – 0.95 (m, 42H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 167.8, 148.0, 138.6, 137.1, 136.1, 136.1, 134.9, 133.6, 127.8, 127.5, 125.0, 121.4, 121.1, 116.4, 104.7, 95.8, 42.0, 20.8, 18.7, 11.3; **HRMS** (EI-TOF) calcd for $C_{40}H_{57}N_2OSi_2$ (M^+): 637.4009, found: 637.3878.




2-(4-methoxy-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5i

1H NMR (400 MHz, $CDCl_3$) δ 9.89 (s, 1H), 8.76 (dd, $J = 7.2, 1.2$ Hz, 1H), 8.68 (dd, $J = 4.4, 1.6$ Hz, 1H), 8.11 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.52 – 7.45 (m, 2H), 7.41 – 7.35 (m, 2H), 7.10 (d, $J = 2.8$ Hz, 1H), 6.93 (dd, $J = 8.4, 2.4$ Hz, 1H), 4.06 (s, 2H), 3.84 (s, 3H), 1.03 – 1.00 (m, 21H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 169.3, 158.6, 148.1, 138.6, 136.2, 134.7, 131.3, 129.2, 127.9, 127.4, 125.0, 121.5, 121.5, 117.7, 116.5, 115.6, 104.8, 95.68, 55.6, 43.0, 18.7, 11.3; **HRMS** (EI-TOF) calcd for $C_{29}H_{37}N_2O_2Si$ (M^+): 473.2624, found: 473.2529.




2-(4-fluoro-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5m

¹H NMR (400 MHz, CDCl₃) δ 9.90 (s, 1H), 8.75 (dd, *J* = 6.8, 1.6 Hz, 1H), 8.69 (dd, *J* = 4.0, 1.2 Hz, 1H), 8.12 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.53 – 7.39 (m, 4H), 7.29 – 7.26 (m, 1H), 7.10-7.05 (m, 1H), 4.09 (s, 2H), 1.05 – 0.98 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 168.5, 161.5 (d, *J* = 247.5 Hz), 148.1, 138.4, 136.2, 134.4, 132.7 (d, *J* = 3.3 Hz), 131.8 (d, *J* = 8.5 Hz), 127.8, 127.3, 125.7 (d, *J* = 9.5 Hz), 121.5 (d, *J* = 2.7 Hz), 119.6, 119.5, 116.4, 116.2 (d, *J* = 21.3 Hz), 103.6 (d, *J* = 2.9 Hz), 97.1, 42.8, 18.6, 11.2; **HRMS** (EI-TOF) calcd for C₂₈H₃₄FN₂OSi (M⁺): 461.2424, found: 461.2326.




2-(4-fluoro-2,6-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5m'

¹H NMR (400 MHz, CDCl₃) δ 9.79 (s, 1H), 8.72 – 8.67 (m, 2H), 8.11 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.50 – 7.44 (m, 2H), 7.39 (dd, *J* = 8.4, 4.4 Hz, 1H), 7.27 – 7.25 (m, 2H), 4.36 (s, 2H), 1.02-0.95 (m, 42H); **¹³C NMR** (101 MHz, CDCl₃) δ 167.3, 162.2 (d, *J* = 247.9 Hz), 148.1, 138.6, 136.2, 135.3, 134.7, 127.8, 127.5, 126.8 (d, *J* = 10.2 Hz), 121.5, 121.2, 119.8 (d, *J* = 22.7 Hz), 116.5, 103.5, 97.8, 41.6, 18.6, 11.3; **HRMS** (EI-TOF) calcd for C₃₉H₅₄FN₂OSi₂ (M⁺): 641.3759, found: 641.3629




2-(4-chloro-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5n

¹H NMR (400 MHz, CDCl₃) δ 9.90 (s, 1H), 8.74 – 8.70 (m, 2H), 8.12 (d, *J* = 8.0 Hz, 1H), 7.56 – 7.32 (m, 7H), 4.09 (s, 2H), 1.05-1.01 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 168.3, 148.2, 138.5, 136.3, 135.4, 134.5, 133.1, 132.7, 131.5, 129.1, 127.9, 127.4, 125.7, 121.7, 121.6, 116.5, 103.5, 97.5, 43.1, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₂₈H₃₄ClN₂OSi (M⁺): 477.2129, found: 477.2032




2-(4-chloro-2,6-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5n

¹H NMR (400 MHz, CDCl₃) δ 9.79 (s, 1H), 8.71 – 8.68 (m, 2H), 8.11 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.52 – 7.44 (m, 4H), 7.40 (dd, *J* = 8.4, 4.4 Hz, 1H), 4.36 (s, 2H), 1.02 – 0.95 (m, 42H); **¹³C NMR** (101 MHz, CDCl₃) δ 167.0, 148.1, 138.6, 137.6, 136.2, 134.7, 132.8, 132.5, 127.8, 127.5, 126.6, 121.5, 121.3, 116.5, 103.2, 98.0, 41.8, 18.6, 11.3; **HRMS** (EI-TOF) calcd for C₃₉H₅₄ClN₂OSi₂ (M⁺): 657.3463, found: 657.3330




2-(4-bromo-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5o

¹H NMR (501 MHz, CDCl₃) δ 9.82 (s, 1H), 8.67 – 8.62 (m, 2H), 8.05 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.63 (d, *J* = 2.0 Hz, 1H), 7.44 – 7.39 (m, 3H), 7.34 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.25 (d, *J* = 8.5 Hz, 1H), 4.00 (s, 2H), 0.95-0.93 (m, 21H); **¹³C NMR** (126 MHz, CDCl₃) δ 168.2, 148.2, 138.4, 136.3, 135.9, 135.5, 134.4, 132.0, 131.7, 127.9, 127.41, 126.0, 121.7, 121.6, 120.9, 116.5, 103.3, 97.7, 43.1, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₂₈H₃₄BrN₂OSi (M⁺): 521.1624, found: 521.1522.




2-(4-bromo-2,5-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide
5o

¹H NMR (501 MHz, CDCl₃) δ 9.85 (s, 1H), 8.75 – 8.74 (m, 2H), 8.16 (d, *J* = 8.0Hz, 1H), 7.71 (s, 2H), 7.55 – 7.49 (m, 2H), 7.45 (dd, *J* = 8.0, 4.0 Hz, 1H), 4.40 (s, 2H), 1.04 – 1.02(m, 42H); **¹³C NMR** (101 MHz, CDCl₃) δ 166.0, 146.8, 137.1, 135.8, 135.7, 134.3, 133.6, 127.0, 126.7, 125.9, 120.4, 120.3, 119.5, 116.0, 102.1, 97.1, 40.9, 17.7, 10.3; **HRMS** (EI-TOF) calcd for C₃₉H₅₄N₂OSi₂ (M⁺): 701.2958, found: 701.2822.




2-(4-acetamido-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide
5p

¹H NMR (400 MHz, CDCl₃) δ 9.94 (s, 1H), 8.76 – 8.68 (m, 2H), 8.12 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.76 – 7.72 (m, 2H), 7.52 – 7.39 (m, 4H), 7.34-7.31 (m, 1H), 4.09 (s, 2H), 2.15 (s, 3H), 0.99 – 0.98 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 169.3, 168.8, 148.3, 138.5, 137.4, 136.3, 134.5, 132.3, 130.7, 127.9, 127.4, 124.5, 124.2, 121.7, 121.6, 120.7, 116.5, 104.6, 95.9, 43.1, 24.6, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₃₀H₃₈N₃O₂Si (M⁺): 500.2733, found:500.2632.




2-(4-acetamido-2,5-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5p

¹H NMR (501 MHz, CDCl₃) δ 9.77 (s, 1H), 8.65 – 8.60 (m, 2H), 8.02 (d, *J* = 7.5 Hz, 1H), 7.64 (s, 3H), 7.41 – 7.35 (m, 2H), 7.30 (dd, *J* = 8.5, 4.5 Hz, 1H), 4.30 (s, 2H), 2.09 (s, 3H), 0.92-0.87 (m, 42H); **¹³C NMR** (126 MHz, CDCl₃) δ 168.9, 168.0, 148.1, 138.5, 137.2, 136.1, 134.6, 127.8, 127.4, 125.6, 124.3, 121.5, 121.3, 116.4, 104.1, 96.5, 41.8, 24.6, 18.6, 11.2; **HRMS** (EI-TOF) calcd for C₄₁H₅₈N₃O₂Si₂ (M⁺): 680.4068, found:680.3928.



2-(4-iodo-2,5-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5q


¹H NMR (501 MHz, CDCl₃) δ 9.82 (s, 1H), 8.66 – 8.62 (m, 2H), 8.04 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.82 (d, *J* = 2.0 Hz, 1H), 7.59 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.44 – 7.39 (m, 2H), 7.33 (dd, *J* = 8.5, 4.5 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 3.98 (s, 2H), 0.97 – 0.92 (m, 21H); **¹³C NMR** (126 MHz, CDCl₃) δ 168.2, 148.2, 141.3, 138.4, 137.9, 136.5, 136.3, 134.4, 131.8, 127.9, 127.4, 126.2, 121.7, 121.6, 116.5, 103.1, 97.7, 92.2, 43.2, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₂₈H₃₄IN₂OSi (M⁺): 569.1485, found: 569.1375



2-(4-iodo-2,5-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5q


¹H NMR (501 MHz, CDCl₃) δ 9.72 (s, 1H), 8.63 – 8.62 (m, 2H), 8.04 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.78 (s, 2H), 7.43 – 7.37 (m, 2H), 7.33 (dd, *J* = 8.5, 4.0 Hz, 1H), 4.27 (s,

2H), 0.92 – 0.90 (m, 42H); ^{13}C NMR (126 MHz, CDCl_3) δ 166.9, 148.0, 141.0, 138.7, 138.4, 136.2, 134.6, 127.8, 127.4, 126.9, 121.5, 121.3, 116.4, 102.8, 98.0, 91.5, 41.9, 18.6, 11.2; **HRMS** (EI-TOF) calcd for $\text{C}_{39}\text{H}_{54}\text{FN}_2\text{OSi}_2$ (M^+): 749.2819, found: 749.2668




2-(4-(tert-butyl)-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5r

^1H NMR (400 MHz, CDCl_3) δ 9.87 (s, 1H), 8.76 (d, $J = 7.6$ Hz, 1H), 8.62 (dd, $J = 4.4$, 1.6 Hz, 1H), 8.08 (dd, $J = 8.4$, 1.2 Hz, 1H), 7.58 (s, 1H), 7.51 – 7.35 (m, 5H), 4.10 (s, 2H), 1.35 (s, 9H), 1.04 – 1.03 (d, $J = 3.2$ Hz, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 169.1, 150.4, 148.0, 138.6, 136.2, 134.7, 134.0, 129.9, 130.0, 127.9, 127.4, 126.4, 123.7, 121.4, 121.5, 116.4, 105.5, 95.0, 43.3, 34.6, 31.3, 18.7, 11.4; **HRMS** (EI-TOF) calcd for $\text{C}_{32}\text{H}_{43}\text{N}_2\text{OSi}$ (M^+): 499.3145, found: 499.3040.




2-(4-(tert-butyl)-2,6-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5r

^1H NMR (400 MHz, CDCl_3) δ 9.77 (s, 1H), 8.72 (d, $J = 7.6$ Hz, 1H), 8.60 (dd, $J = 4.4$, 1.6 Hz, 1H), 8.08 (dd, $J = 8.4$, 1.6 Hz, 1H), 7.56 – 7.55 (m, 2H), 7.49 – 7.41 (m, 2H), 7.35 (dd, $J = 8.4$, 4.4 Hz, 1H), 4.37 (s, 2H), 1.37 (s, 9H), 1.02 – 0.99 (m, 42H); ^{13}C NMR (101 MHz, CDCl_3) δ 167.8, 150.3, 147.8, 138.7, 136.3, 136.1, 134.9, 130.1, 127.8, 127.5, 124.8, 121.4, 121.0, 116.4, 105.1, 95.5, 41.9, 34.6, 31.3, 18.7, 11.4; **HRMS** (EI-TOF) calcd for $\text{C}_{43}\text{H}_{63}\text{N}_2\text{OSi}_2$ (M^+): 679.4479, found: 649.4338.




2-(4-nitro-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5s

¹H NMR (400 MHz, CDCl₃) δ 9.94 (s, 1H), 8.73 – 8.70 (m, 2H), 8.39 (d, *J* = 2.4 Hz, 1H), 8.20 – 8.14 (m, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.52 – 7.51 (m, 2H), 7.44 (dd, *J* = 8.4, 4.4 Hz, 1H), 4.22 (s, 2H), 1.06 – 1.02 (m, 21H); **¹³C NMR** (101 MHz, CDCl₃) δ 167.1, 148.3, 147.2, 143.9, 138.5, 136.4, 134.3, 131.3, 128.0, 127.8, 127.5, 125.7, 123.4, 122.0, 121.8, 116.7, 102.5, 99.5, 43.4, 18.7, 11.3; **HRMS** (EI-TOF) calcd for C₂₈H₃₄N₃O₃Si (M⁺): 488.2369, found: 488.2274.



2-(4-nitro-2,6-bis((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5s

¹H NMR (501 MHz, CDCl₃) δ 9.83 (s, 1H), 8.72 – 8.66 (m, 2H), 8.32 (s, 2H), 8.14 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.50 – 7.42 (m, 3H), 4.50 (s, 2H), 1.02 – 0.99 (m, 42H); **¹³C NMR** (101 MHz, CDCl₃) δ 165.8, 148.0, 146.7, 145.6, 138.3, 136.2, 134.3, 127.7, 127.4, 126.6, 126.7, 121.4, 121.5, 116.5, 102.2, 99.7, 42.1, 18.5, 11.1; **HRMS** (EI-TOF) calcd for C₃₉H₅₄N₃O₃Si₂ (M⁺): 668.3704, found: 668.3571.




2-(4,5-dimethoxy-2-((triisopropylsilyl)ethynyl)phenyl)-N-(quinolin-8-yl)acetamide 5t

^1H NMR (400 MHz, CDCl_3) δ 9.93 (s, 1H), 8.74 (dd, $J = 7.2, 1.6$ Hz, 1H), 8.68 (dd, $J = 4.0, 1.6$ Hz, 1H), 8.11 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.52 – 7.45 (m, 2H), 7.39 (dd, $J = 8.4, 4.4$ Hz, 1H), 7.04 (s, 1H), 6.96 (s, 1H), 4.08 (s, 2H), 3.92 (d, $J = 3.2$ Hz, 6H), 1.05 – 1.00 (m, 21H); **^{13}C NMR** (101 MHz, CDCl_3) δ 169.1, 149.8, 148.2, 148.0, 138.6, 136.2, 134.6, 130.4, 127.9, 127.4, 121.6, 116.5, 116.1, 115.1, 112.8, 105.0, 94.0, 56.2, 56.1, 43.5, 18.7, 11.4; **HRMS** (EI-TOF) calcd for $\text{C}_{30}\text{H}_{39}\text{N}_2\text{O}_3\text{Si}$ (M^+): 503.2730, found: 503.2622.


2.3 Mechanistic Investigation

a) control experiments without NBS




A mixture of **1a** (0.1 mmol), $\text{Pd}(\text{OAc})_2$ (10 mol%), **2** alkyne (1.2 mmol), Boc-D-Ala-OH (20 mol%), and AgTHF (1.2 mmol), tert-amyl alcohol (1 mL) in a 35 mL sealed tube was conducted at $30\text{ }^\circ\text{C}$ for 10 h under air atmosphere. no product **3a** was detected.

b) control experiments without AgTFA




A mixture of **1a** (0.1 mmol), $\text{Pd}(\text{OAc})_2$ (10 mol%), **2** alkyne (1.2 mmol), Boc-D-Ala-OH (20 mol%), and NBS (1.2 mmol), tert-amyl alcohol (1 mL) in a 35 mL sealed tube was conducted at $30\text{ }^\circ\text{C}$ for 10 h under air atmosphere. no product **3a** was detected.

c) control experiments use bromoalkyne instead of AgTFA, NBS and 2




A mixture of **1a** (0.1 mmol), Pd(OAc)₂ (10 mol%), bromoalkyne (1.2 mmol), Boc-D-Ala-OH (20 mol%), tert-amyl alcohol (1 mL) in a 35 mL sealed tube was conducted at 30 °C for 10 h under air atmosphere. the alkynylation product **3a** could be obtained in 40% yield.

d) detection of bromoalkyne



A mixture of **1a** (0.1 mmol), Pd(OAc)₂ (10 mol%), **2** alkynyl (0.12 mmol), N-Boc-phe-OH (20 mol%), AgOAc (2.4 mmol) and NBS (0.12 mmol), t-AmylOH (1 mL) in a 35 mL sealed tube was conducted at rt for 24 h under air atmosphere. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. After filtration, the mixture was analyzed by GC/MS.




流路号:2 保留时间:5.380(扫描数:477)


质量峰:310

原始模式:平均 5.375-5.385(476-478) 基峰:217(476967)

背景模式:从峰校准 组 1 - 事件 1




e) experiments with radical scavengers 1,1-diphenylethylene




A mixture of **1a** (0.1 mmol), $\text{Pd}(\text{OAc})_2$ (10 mol%), **2** alkyne (1.2 mmol), Boc-D-Ala-OH (20 mol%), NBS (1.2 mmol), AgTHF (1.2 mmol) and 1,1-diphenylethylene (1.0 mmol), tert-amyl alcohol (1 mL) in a 35 mL sealed tube was conducted at 30 °C for 10 h under air atmosphere. **3a** were obtained in 48 % yield.

f) experiments with radical scavengers TEMPO




A mixture of **1a** (0.1 mmol), $\text{Pd}(\text{OAc})_2$ (10 mol%), **2** alkyne (1.2 mmol), Boc-D-Ala-OH (20 mol%), NBS (1.2 mmol), AgTHF (1.2 mmol) and TEMPO (1.0 mmol), tert-amyl alcohol (1 mL) in a 35 mL sealed tube was conducted at 30 °C for 10 h under air atmosphere. **3a** were obtained in 56 % yield.


2.4 Diversication of ortho-Alkynylated phenylacetic amides



A mixture of **3a** (0.5 mmol, 256 mg), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (10.0 eq, 5.0 mmol, 0.6 mL), MeOH (2 mL) in a 35 mL sealed tube was stirred at 80 °C for 24 h. The reaction mixture was concentrated under reduced pressure and then purified by column chromatography on silica gel to give the corresponding product **3ab** (66%, 132.2 mg).




A mixture of **3ab** (0.3 mmol, 120 mg), TBAF (4.0 eq, 1.2 mmol, 313.8 mg), THF (1 mL) in a 35 mL sealed tube was stirred at 25 °C for 1.5 h. The reaction mixture was concentrated under reduced pressure and then purified by column chromatography on silica gel to give the corresponding product **3ac** (85%, 62.3 mg). ^1H NMR (501 MHz, CDCl_3) δ 7.22 (d, J = 1.5 Hz, 1H), 7.14 – 7.13 (m, 1H), 7.04 – 7.03 (m, J = 8.0, 1.7 Hz, 1H), 4.20 (q, J = 7.0 Hz, 1H), 3.59 (s, 3H), 3.17 (s, 1H), 2.35 (d, J = 7.0 Hz, 2H), 1.82 – 1.73 (m, 1H), 1.41 (d, J = 7.0 Hz, 3H), 0.82 (d, J = 6.5 Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 175.1, 140.6, 140.5, 133.7, 130.4, 126.6, 121.3, 82.1, 81.1, 52.1, 44.8, 42.9, 30.1, 22.5, 18.5.



A 30 mL reaction tube equipped with a magnetic stir bar was charged with **3ac** (0.2 mmol) followed by CuI (10 mol%), BnN₃ (0.4 mmol) and DMF (1 mL). The reaction tube was sealed with a Teflon cap and the reaction mixture was stirred at 60 °C for 14 h, after which it was diluted with water (5 mL) and extracted by ethyl acetate (5 mL×3). The organic phase was combined and washed with aqueous HCl (1.0 N, 5 mL) and brine (5 mL). The reaction mixture was dried by Na₂SO₄ and concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the corresponding product **3ad** (80%, 60.4 mg). ¹H NMR (501 MHz, CDCl₃) δ 7.73 (s, 1H), 7.46 – 7.33 (m, 7H), 7.19 – 7.17 (m, 1H), 5.68 – 5.61 (m, 2H), 4.29 (q, *J* = 7.0 Hz, 1H), 3.62 (s, 3H), 2.49 (d, *J* = 7.0 Hz, 2H), 1.93 – 1.87 (m, 2H), 1.50 (d, *J* = 7.5 Hz, 3H), 0.94 (d, *J* = 6.0 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 175.6, 147.5, 140.6, 136.2, 134.8, 130.7, 129.7, 129.4, 129.2, 128.8, 128.2, 127.2, 122.4, 54.3, 52.0, 45.0, 41.1, 30.2, 22.5, 22.5, 19.1; HRMS (EI-TOF) calcd for C₂₄H₃₄N₄OSi (M⁺): 378.2182, found: 378.2163.

2.5. Gram-Scale Reaction





A mixture of **1a** (2 mmol), Pd(OAc)₂ (10 mol%), **2** alkynyl (2.4 mmol), N-Boc-phe-OH (20 mol%), AgOAc (2.4 mmol) and NBS (2.4mmol), DCE (5 mL) in a 35 mL sealed tube was conducted at rt for 16 h under air atmosphere. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel to give the corresponding product **3a** (72%).

2.6 Crystal structure data

Single-crystal X-ray Diffraction

The diffraction data of crystals were collected on a Rigaku XtaLAB Synergy CCD diffractometer with graphite monochromated Cu-K α radiation ($\lambda = 1.54056 \text{ \AA}$) at 293 K. Absorption corrections were applied by SADABS^[4]. All the structures were solved by direct methods and refined by full-matrix least-squares method on F^2 using SHELXTL-2014.^[5] All non-hydrogen atoms were refined with anisotropic displacement parameters. The hydrogen atoms of the ligand were generated geometrically.



X-ray data for 3n

3n


Identification code	1-64-5
Empirical formula	C ₃₄ H ₄₄ N ₂ OSi
Formula weight	524.8
Temperature/K	293
Crystal system	triclinic
Space group	P-1
a/Å	8.8134(2)
b/Å	10.3559(3)
c/Å	18.0350(4)
α /°	100.993(2)
β /°	95.022(2)
γ /°	92.933(2)
Volume/Å ³	1605.78(7)
Z	2
$\rho_{\text{calc}}/\text{cm}^3$	1.085
μ/mm^{-1}	0.835
F(000)	568
Crystal size/mm ³	0.3 × 0.3 × 0.1
2 θ range for data collection/°	5.016 to 153.632
Index ranges	-11 ≤ h ≤ 9, -13 ≤ k ≤ 13, -21 ≤ l ≤ 22
Reflections collected	17410
Independent reflections	6387 [R _{int} = 0.0392, R _{sigma} = 0.0437]
Data/restraints/parameters	6387/3/349
Goodness-of-fit on F ²	1.199
Final R indexes [I ≥ 2 σ (I)]	R ₁ = 0.0837, wR ₂ = 0.2634
Final R indexes [all data]	R ₁ = 0.0943, wR ₂ = 0.2881
Largest diff. peak/hole / e Å ⁻³	1.15/-0.40

2.7. Chirality retention experiment

Enantiomeric excess of final product was determined by HPLC with chiralcel AD-H column. eluent: Hex/iPrOH= 99/1, rate= 0.6 mL/min, $\lambda = 220$ nm





#	time	Area	Height	Area %
1	14.033	1988415	114040	49.434
2	16.673	2033923	95909	50.566





#	time	Area	Height	Area %
1	13.754	3809813	213618	100
2	16.952	0	0	0

4. NMR Spectra



3a





3b





3c





3d





3e





3f





3g





3h





3i





3j





3j





3k





3l





3m





3n





30





5a





5b





5c





5d





5e





5f





5g





5h





5i





5j





5k





5k





5i





5m





5m





5n





5n





50





50





5p





5p





5q





5q





5r





5r





5s





5s



5t



3ac



3ad

